Ruxolitinib for Chuvash Polycythemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01730755|
Expanded Access Status : No longer available
First Posted : November 21, 2012
Last Update Posted : May 14, 2018
|Condition or disease||Intervention/treatment|
|Erythrocytosis, Familial, 2||Drug: Ruxolitinib|
Study involvement will last for 48 weeks. There will be approximately 11 visits through week 48. Visits may take up to 2-3 hours to complete and occur every 4 weeks for the first 24 weeks, then every 12 weeks until week 48.
During each study visit, any or all of the following procedures may occur:
- List current medications and participant general health
- Obtain blood pressure, body weight, body temperature, respiratory rate and heart rate
- Measure Spleen by examination
- Obtain an abdominal MRI to evaluate spleen and any pre-existing or new blood clots
- Obtain blood samples for safety tests and to monitor kidney/liver function.
- Questionnaires for participant to complete regarding symptoms related to disease.
- Ruxolitinib dosing may be increased after 4 weeks if needed. The dose of the ruxolitinib may be reduced related to side effects.
|Study Type :||Expanded Access|
|Official Title:||Ruxolitinib for Chuvash Polycythemia|
- Drug: Ruxolitinib
Ruxolitinib 10 mg tablets twice dailyOther Name: Jakafi
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01730755
|United States, Missouri|
|Washington University School of Medicine|
|Saint Louis, Missouri, United States, 63110|